Finance

Lists
BDTX:NASDAQ
Black Diamond Therapeutics Inc
$1.89
+0.53%
(+0.0100) 1D
$1.89
0.00% (0.00)
After hours
Closed: Oct 2, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BDTX...
Open
$1.91
High
$1.94
Low
$1.88
Mkt. cap
108.59M
Avg. vol.
576.42K
Volume
472.18K
52-wk high
$4.94
52-wk low
$1.60
EPS
-$0.74
Beta
3.32
Shares outstanding
57.45M
No. of employees
21
Open
$1.91
High
$1.94
Low
$1.88
Mkt. cap
108.59M
Avg. vol.
576.42K
Volume
472.18K
52-wk high
$4.94
52-wk low
$1.60
EPS
-$0.74
Beta
3.32
Shares outstanding
57.45M
No. of employees
21
News stories
From web sources and news partners
About Black Diamond Therapeutics Inc
CEO-
Employees21
Founded2014
Headquarters-
SectorBiotechnology
Websiteblackdiamondtherapeutics.com
Analyst ratings
Based on 7 analysts giving stock ratings to BDTX in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for BDTX in the last 3 months.
Highest
Current $1.89
$14.00 (+640.74%)
Average
$10.33 (+446.56%)
Lowest
$8.00 (+323.28%)
Analyst
Recommendation
Action
Price target
Projected
Date
Sean McCutcheon
Raymond James
Buy
Maintained
$11.00
+482%
08/06/2026
Maury Raycroft
Jefferies
Buy
Maintained
$10.00
+429.1%
08/06/2026
Robert Driscoll
Wedbush
Buy
Reiterated
$14.00
+640.7%
08/06/2026
Laura Prendergast
Stifel Nicolaus
Buy
Maintained
$8.00
+323.3%
08/06/2026
Kelsey Goodwin
Piper Sandler
Buy
Maintained
$8.00
+323.3%
08/06/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$11.00
+482%
08/06/2026
Marc Frahm
TD Cowen
Buy
Maintained
-
-
08/05/2026
Last report
Aug 5, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.17 / -$0.20
+15.00%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
7.44M
6.30M
7.00M
7.39M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.54M
3.97M
4.26M
4.66M
Operating expense
10.98M
10.26M
11.26M
12.06M
Total operating expenses
10.98M
10.26M
11.26M
12.06M
Operating income
-10.98M
-10.26M
-11.26M
-12.06M
Other non operating income
1.32M
1.16M
1.20M
1.23M
EBT including unusual items
-8.50M
-15.12M
-9.04M
-9.90M
EBT excluding unusual items
-8.50M
-7.92M
-9.04M
-9.90M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-8.50M
-15.12M
-9.04M
-9.90M
Net profit margin
-
-
-
-
Earnings per share
-0.15
-0.14
-0.16
-0.17
Interest and investment income
1.16M
1.18M
1.02M
922.00K
Interest expense
-
-
-
-
Net interest expenses
1.16M
1.18M
1.02M
922.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-10.89M
-10.20M
-11.23M
-12.03M
Gain or loss from assets sale
-1.00K
-3.00K
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps